Understanding cytokine and growth factor receptor activation mechanisms

Critical Reviews in Biochemistry and Molecular Biology

Volumn 47, Issue 6, 2012, Pages 502-530

  Atanasova, Mariya ^a   Whitty, Adrian ^a  

^a USA   (United States)

Author keywords

Agonist antibodies; Bell shaped dose response; Erythropoietin receptor; Ligand induced dimerization; Ligand induced oligomerization; Receptor pre association; Receptor ligand cross reactivity; Small molecule receptor agonists

Indexed keywords

CYTOKINE; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR; ION CHANNEL; OLIGOMER;

CROSS REACTION; DIMERIZATION; LIGAND BINDING; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; REVIEW;

ANIMALS; CYTOKINES; HUMANS; ION CHANNELS; LIGANDS; PROTEIN MULTIMERIZATION; RECEPTORS, CYTOKINE; RECEPTORS, ERYTHROPOIETIN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, GROWTH FACTOR;

EID: 84867564127     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2012.729561     Document Type: Review

References (218)

1. Abe S, Sasaki R, Masuda S. 2011. An extra high dose of erythropoietin fails to support the proliferation of erythropoietin dependent cell lines. Cytotechnology 63:101-109.
2. Adar R, Monsonego-Ornan E, David P, Yayon A. 2002. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J Bone Miner Res 17:860-868. (Pubitemid 34441903)
3. Airaksinen MS, Saarma M. 2002. The GDNF family: Signalling, biological functions and therapeutic value. Nat Rev Neurosci 3:383-394. (Pubitemid 135706635)
4. Airaksinen MS, Titievsky A, Saarma M. 1999. GDNF family neurotrophic factor signaling: Four masters, one servant? Mol Cell Neurosci 13:313-325. (Pubitemid 29256872)
5. Alvarado D, Klein DE, Lemmon MA. 2010. Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Cell 142:568-579.
6. Alves NL, Arosa FA, van Lier RA. 2007. Common γ chain cytokines: Dissidence in the details. Immunol Lett 108:113-120. (Pubitemid 46198953)
7. Arduini RM, Strauch KL, Runkel LA, Carlson MM, Hronowski X, Foley SF, Young CN, Cheng W, Hochman PS, Baker DP. 1999. Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains. Protein Sci 8:1867-1877. (Pubitemid 29430487)
8. Artemenko EO, Egorova NS, Arseniev AS, Feofanov AV. 2008. Transmembrane domain of EphA1 receptor forms dimers in membrane-like environment. Biochim Biophys Acta 1778:2361-2367.
9. Ballinger MD, Wells JA. 1998. Will any dimer do? Nat Struct Biol 5:938-940. (Pubitemid 28506622)
10. Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNF β complex: Implications for TNF receptor activation. Cell 73:431-445. (Pubitemid 23143344)
11. Barton VA, Hall MA, Hudson KR, Heath JK. 2000. Interleukin-11 signals through the formation of a hexameric receptor complex. J Biol Chem 275:36197-36203.
12. Baselga J, Swain SM. 2009. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475.
13. Bennasroune A, Fickova M, Gardin A, Dirrig-Grosch S, Aunis D, Crémel G, Hubert P. 2004. Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol Biol Cell 15:3464-3474. (Pubitemid 38850137)
14. Bocharov EV, Mineev KS, Volynsky PE, Ermolyuk YS, Tkach EN, Sobol AG, Chupin V V, Kirpichnikov MP, Efremov RG, Arseniev AS. 2008. Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state. J Biol Chem 283:6950-6956.
15. Bodmer JL, Schneider P, Tschopp J. 2002. The molecular architecture of the TNF superfamily. Trends Biochem Sci 27:19-26. (Pubitemid 34131621)
16. Boger DL, Goldberg J. 2001. Cytokine receptor dimerization and activation: Prospects for small molecule agonists. Bioorg Med Chem 9:557-562. (Pubitemid 32208576)
17. Böni-Schnetzler M, Pilch PF. 1987. Mechanism of epidermal growth factor receptor autophosphorylation and high-affinity binding. Proc Natl Acad Sci USA 84:7832-7836.
18. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. 2003. Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/gp130 complex. Science 300:2101-2104. (Pubitemid 36760138)
19. Boulanger MJ, Garcia KC. 2004. Shared cytokine signaling receptors: structural insights from the gp130 system. Adv Protein Chem 68:107-146. (Pubitemid 41184480)
20. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ. 2005. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 12:814-821. (Pubitemid 43086257)
21. Brummer T, Schmitz-Peiffer C, Daly RJ. 2010. Docking proteins. FEBS J 277:4356-4369.
22. Bruno MA, Clarke PB, Seltzer A, Quirion R, Burgess K, Cuello AC, Saragovi HU. 2004. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. J Neurosci 24:8009-8018. (Pubitemid 39280820)
23. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. 2000. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288:2351-2354. (Pubitemid 30448156)
24. Chen D, Brahimi F, Angell Y, Li YC, Moscowicz J, Saragovi HU, Burgess K. 2009. Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals. ACS Chem Biol 4:769-781.
25. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL, Bussel JB. 2011. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study. Lancet 377:393-402.
26. Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I. 2010. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature 464:783-787.
27. Clayton AH, Walker F, Orchard SG, Henderson C, Fuchs D, Rothacker J, Nice EC, Burgess AW. 2005. Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. J Biol Chem 280:30392-30399. (Pubitemid 41216222)
28. Cochet C, Kashles O, Chambaz EM, Borrello I, King CR, Schlessinger J. 1988. Demonstration of epidermal growth factor-induced receptor dimerization in living cells using a chemical covalent cross-linking agent. J Biol Chem 263:3290-3295. (Pubitemid 18072785)
29. Colangelo AM, Bianco MR, Vitagliano L, Cavaliere C, Cirillo G, De Gioia L, Diana D, Colombo D, Redaelli C, Zaccaro L, Morelli G, Papa M, Sarmientos P, Alberghina L, Martegani E. 2008. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J Neurosci 28:2698-2709. (Pubitemid 351398884)
30. Constantinescu SN, Huang LJ, Nam H, Lodish HF. 2001a. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell 7:377-385. (Pubitemid 32206505)
31. Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF. 2001b. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci USA 98:4379-4384. (Pubitemid 32294985)
32. Cunningham BC, Bass S, Fuh G, Wells JA. 1990. Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 250:1709-1712. (Pubitemid 120031878)
33. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clauser KR, Wells JA. 1991. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254:821-825. (Pubitemid 21917402)
34. Cwirla SE, Balasubramanian P, Duffin DJ, Wagstrom CR, Gates CM, Singer SC, Davis AM, Tansik RL, Mattheakis LC, Boytos CM, Schatz PJ, Baccanari D P, Wrighton NC, Barrett RW, Dower WJ. 1997. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276:1696-1699. (Pubitemid 27421976)
35. Day ES, Cachero TG, Qian F, Sun Y, Wen D, Pelletier M, Hsu YM, Whitty A. 2005. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 44:1919-1931. (Pubitemid 40223621)
36. de Bakker BI, Bodnár A, van Dijk EM, Vámosi G, Damjanovich S, Waldmann TA, van Hulst NF, Jenei A, Garcia-Parajo MF. 2008. Nanometer-scale organization of the α subunits of the receptors for IL2 and IL15 in human T lymphoma cells. J Cell Sci 121:627-633. (Pubitemid 351524161)
37. De Meyts P, Wallach B, Christoffersen CT, Ursø B, Grønskov K, Latus LJ, Yakushiji F, Ilondo MM, Shymko RM. 1994. The insulin-like growth factor-I receptor. Structure, ligand-binding mechanism and signal transduction. Horm Res 42:152-169. (Pubitemid 24336143)
38. Deng B, Banu N, Malloy B, Hass P, Wang JF, Cavacini L, Eaton D, Avraham H. 1998. An agonist murine monoclonal antibody to the human c-Mpl receptor stimulates megakaryocytopoiesis. Blood 92:1981-1988. (Pubitemid 28446688)
39. DeWitt A, Iida T, Lam HY, Hill V, Wiley HS, Lauffenburger DA. 2002. Affinity regulates spatial range of EGF receptor autocrine ligand binding. Dev Biol 250:305-316. (Pubitemid 35216417)
40. Dosch DD, Ballmer-Hofer K. 2010. Transmembrane domain-mediated orientation of receptor monomers in active VEGFR-2 dimers. FASEB J 24:32-38.
41. Doyle ML, Tian SS, Miller SG, Kessler L, Baker AE, Brigham-Burke MR, Dillon SB, Duffy KJ, Keenan RM, Lehr R, Rosen J, Schneeweis LA, Trill J, Young PR, Luengo JI, Lamb P. 2003. Selective binding and oligomerization of the murine granulocyte colony-stimulating factor receptor by a low molecular weight, nonpeptidyl ligand. J Biol Chem 278:9426-9434. (Pubitemid 36800433)
42. Dusanter-Fourt I, Muller O, Ziemiecki A, Mayeux P, Drucker B, Djiane J, Wilks A, Harpur AG, Fischer S, Gisselbrecht S. 1994. Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin-erythropoietin receptor chimera expressed in lymphoid cells. EMBO J 13:2583-2591.
43. Dustin ML, Golan DE, Zhu DM, Miller JM, Meier W, Davies EA, van der Merwe PA. 1997. Low affinity interaction of human or rat T cell adhesion molecule CD2 with its ligand aligns adhering membranes to achieve high physiological affinity. J Biol Chem 272:30889-30898. (Pubitemid 27527532)
44. Ebie AZ, Fleming KG. 2007. Dimerization of the erythropoietin receptor transmembrane domain in micelles. J Mol Biol 366:517-524. (Pubitemid 46136203)
45. Elliott S, Lorenzini T, Yanagihara D, Chang D, Elliott G. 1996. Activation of the erythropoietin (EPO) receptor by bivalent anti-EPO receptor antibodies. J Biol Chem 271:24691-24697. (Pubitemid 26333213)
46. Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Nophar Y, Hadas E, Leitner O, Wallach D. 1990. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 265:14497-14504.
47. England BP, Balasubramanian P, Uings I, Bethell S, Chen MJ, Schatz PJ, Yin Q, Chen Y F, Whitehorn EA, Tsavaler A, Martens CL, Barrett RW, McKinnon M. 2000. A potent dimeric peptide antagonist of interleukin-5 that binds two interleukin-5 receptor alpha chains. Proc Natl Acad Sci USA 97:6862-6867. (Pubitemid 30412805)
48. Ferguson KM. 2008. Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 37:353-373.
49. Frêche B, Guillaumot P, Charmetant J, Pelletier L, Luquain C, Christiansen D, Billaud M, Manié SN. 2005. Inducible dimerization of RET reveals a specific AKT deregulation in oncogenic signaling. J Biol Chem 280:36584-36591. (Pubitemid 41587734)
50. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. 1992. Rational design of potent antagonists to the human growth hormone receptor. Science 256:1677-1680.
51. Gadella TW Jr, Jovin TM. 1995. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation. J Cell Biol 129:1543-1558.
52. Gavutis M, Jaks E, Lamken P, Piehler J. 2006. Determination of the two-dimensional interaction rate constants of a cytokine receptor complex. Biophys J 90:3345-3355.
53. Gavutis M, Lata S, Lamken P, Müller P, Piehler J. 2005. Lateral ligand-receptor interactions on membranes probed by simultaneous fluorescence-interference detection. Biophys J 88:4289-4302. (Pubitemid 40991139)
54. Germain RN. 1997. T-cell signaling: The importance of receptor clustering. Curr Biol 7:R640-R644. (Pubitemid 27441819)
55. Ghoreschi K, Laurence A, O'Shea JJ. 2009. Janus kinases in immune cell signaling. Immunol Rev 228:273-287.
56. Goldberg J, Jin Q, Ambroise Y, Satoh S, Desharnais J, Capps K, Boger DL. 2002. Erythropoietin mimetics derived from solution phase combinatorial libraries. J Am Chem Soc 124:544-555. (Pubitemid 34101160)
57. Graham H, Peng C. 2006. Activin receptor-like kinases: structure, function and clinical implications. Endocr Metab Immune Disord Drug Targets 6:45-58. (Pubitemid 43796713)
58. Guy PM, Platko J V, Cantley LC, Cerione RA, Carraway KL 3rd. 1994. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91:8132-8136.
59. Harrison DA. 2012. The Jak/STAT pathway. Cold Spring Harb Perspect Biol 4. DOI: 10.1101/cshperspect.a011205
60. Heldin CH, Ostman A. 1996. Ligand-induced dimerization of growth factor receptors: Variations on the theme. Cytokine Growth Factor Rev 7:3-10. (Pubitemid 27202661)
61. Heldin CH. 1995. Dimerization of cell surface receptors in signal transduction. Cell 80:213-223.
62. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. 2003. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo-and heterodimers depends on relative HER2 levels. J Biol Chem 278:23343-23351. (Pubitemid 36830149)
63. Himanen JP, Saha N, Nikolov DB. 2007. Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell Biol 19:534-542. (Pubitemid 350016850)
64. Himanen JP, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L, Rajashankar KR, Mensinga A, Lackmann M, Nikolov DB, Dhe-Paganon S. 2010. Architecture of Eph receptor clusters. Proc Natl Acad Sci USA 107:10860-10865.
65. Hofman EG, Bader AN, Voortman J, van den Heuvel DJ, Sigismund S, Verkleij AJ, Gerritsen HC, van Bergen en Henegouwen PM. 2010. Ligand-induced EGF receptor oligomerization is kinase-dependent and enhances internalization. J Biol Chem 285:39481-39489.
66. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, Tinel A, Deperthes D, Calderara S, Schulthess T, Engel J, Schneider P, Tschopp J. 2003. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 23:1428-1440. (Pubitemid 36177050)
67. Horsten U, Schmitz-Van de Leur H, Müllberg J, Heinrich PC, Rose-John S. 1995. The membrane distal half of gp130 is responsible for the formation of a ternary complex with IL-6 and the IL-6 receptor. FEBS Lett 360:43-46.
68. Huang YF, Liu H, Xiong X, Chen Y, Tan W. 2009. Nanoparticle-mediated IgE-receptor aggregation and signaling in RBL mast cells. J Am Chem Soc 131:17328-17334.
69. Ilondo MM, Damholt AB, Cunningham BA, Wells JA, De Meyts P, Shymko RM. 1994. Receptor dimerization determines the effects of growth hormone in primary rat adipocytes and cultured human IM-9 lymphocytes. Endocrinology 134:2397-2403. (Pubitemid 24170849)
70. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, Van der Heyden J, Uze G, Schreiber G. 2006. Inquiring into the differential action of interferons (IFNs): An IFN-α2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-β. Mol Cell Biol 26:1888-1897.
71. Jaks E, Gavutis M, Uzé G, Martal J, Piehler J. 2007. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366:525-539. (Pubitemid 46136210)
72. Jang IK, Zhang J, Gu H. 2009. Grb2, a simple adapter with complex roles in lymphocyte development, function, and signaling. Immunol Rev 232:150-159.
73. Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, Wilson WD, Xiao G, Blanchi B, Sun YE, Ye K. 2010. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA 107:2687-2692.
74. Jang SW, Okada M, Sayeed I, Xiao G, Stein D, Jin P, Ye K. 2007. Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death. Proc Natl Acad Sci USA 104:16329-16334. (Pubitemid 350099404)
75. Jenei A, Kormos J, Szentesi G, Veres AJ, Varga S, Bodnár A, Damjanovich S, Mátyus L. 2009. Non-random distribution of interleukin receptors on the cell surface. Chemphyschem 10:1577-1585.
76. Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrock BW, Fox GM. 1996. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell 85:1113-1124. (Pubitemid 26231176)
77. Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Hoey K, Livnah O, Wrighton NC, Middleton SA, Loughney DA, Stura EA, Dower WJ, Mulcahy LS, Wilson IA, Jolliffe LK. 1998. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 37:3699-3710. (Pubitemid 28162924)
78. Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Kroon D, Freedy J, Zivin RA, Mulcahy LS, Jolliffe LK. 1997. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol 4:939-950. (Pubitemid 28050378)
79. Jones DH, Rigby AC, Barber KR, Grant CW. 1997. Oligomerization of the EGF receptor transmembrane domain: A 2H NMR study in lipid bilayers. Biochemistry 36:12616-12624. (Pubitemid 27446687)
80. Kai M, Motoki K, Yoshida H, Emuta C, Chisaka Y, Tsuruhata K, Endo C, Muto M, Shimabe M, Nishiyama U, Hagiwara T, Matsumoto A, Miyazaki H, Kataoka S. 2008. Switching constant domains enhances agonist activities of antibodies to a thrombopoietin receptor. Nat Biotechnol 26:209-211. (Pubitemid 351225953)
81. Kalie E, Jaitin DA, Podoplelova Y, Piehler J, Schreiber G. 2008. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem 283:32925-32936.
82. Kaneko E, Kawahara M, Ueda H, Nagamune T. 2012. Growth control of genetically modified cells using an antibody/c-Kit chimera. J Biosci Bioeng 113:641-646.
83. Kawahara M, Chen J, Sogo T, Teng J, Otsu M, Onodera M, Nakauchi H, Ueda H, Nagamune T. 2011. Growth promotion of genetically modified hematopoietic progenitors using an antibody/c-Mpl chimera. Cytokine 55:402-408.
84. Kawahara M, Ueda H, Tsumoto K, Kumagai I, Mahoney W, Nagamune T. 2002. Selection of highly productive mammalian cells based on an inducible growth advantage using an antibody/receptor chimera. J Biosci Bioeng 93:399-404. (Pubitemid 34971759)
85. Kawahara M, Ueda H, Tsumoto K, Kumagai I, Nagamune T. 2007. Mimicry of erythropoietin and interleukin-6 signalling by an antibody/cytokine receptor chimera in murine myeloid 32D cells. J Biochem 141:563-571. (Pubitemid 351455303)
86. Kessler C, Greindl A, Breuer B, Haberl U, Rybka A, Emgenbroich M, Frank HG, Pötgens AJ. 2012. Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities. Cytokine 57:226-237.
87. Kimura T, Kaburaki H, Tsujino T, Ikeda Y, Kato H, Watanabe Y. 1998. A non-peptide compound which can mimic the effect of thrombopoietin via c-Mpl. FEBS Lett 428:250-254. (Pubitemid 28319693)
88. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y. 1999. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96:4995-5000. (Pubitemid 29214524)
89. Kleiman LB, Maiwald T, Conzelmann H, Lauffenburger DA, Sorger PK. 2011. Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding. Mol Cell 43:723-737.
90. Klein P, Mattoon D, Lemmon MA, Schlessinger J. 2004. A structure-based model for ligand binding and dimerization of EGF receptors. Proc Natl Acad Sci USA 101:929-934. (Pubitemid 38160561)
91. Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, Kerber G, Citri A, Lavi S, Eilam R, Chalifa-Caspi V, Eshhar Z, Pikarsky E, Pinkas-Kramarski R, Bacus SS, Yarden Y. 2005. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem 280:8503-8512. (Pubitemid 40349755)
92. Kowalczyk C, Dunkel N, Willen L, Casal ML, Mauldin EA, Gaide O, Tardivel A, Badic G, Etter AL, Favre M, Jefferson DM, Headon DJ, Demotz S, Schneider P. 2011. Molecular and therapeutic characterization of anti-ectodysplasin A receptor (EDAR) agonist monoclonal antibodies. J Biol Chem 286:30769-30779.
93. Krause CD, Mei E, Xie J, Jia Y, Bopp MA, Hochstrasser RM, Pestka S. 2002. Seeing the light: Preassembly and ligand-induced changes of the interferon γ receptor complex in cells. Mol Cell Proteomics 1:805-815.
94. Krause S, Schmoldt HU, Wentzel A, Ballmaier M, Friedrich K, Kolmar H. 2007. Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists. FEBS J 274:86-95. (Pubitemid 44952900)
95. Kruse N, Tony HP, Sebald W. 1992. Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J 11:3237-3244.
96. Kubatzky KF, Liu W, Goldgraben K, Simmerling C, Smith SO, Constantinescu SN. 2005. Structural requirements of the extracellular to transmembrane domain junction for erythropoietin receptor function. J Biol Chem 280:14844-14854. (Pubitemid 40562834)
97. Kubatzky KF, Ruan W, Gurezka R, Cohen J, Ketteler R, Watowich SS, Neumann D, Langosch D, Klingmüller U. 2001. Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptor. Curr Biol 11:110-115. (Pubitemid 32116843)
98. Lamken P, Lata S, Gavutis M, Piehler J. 2004. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. J Mol Biol 341:303-318. (Pubitemid 39090652)
99. Langenheim JF, Tan D, Walker AM, Chen WY. 2006. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists. Mol Endocrinol 20:661-674. (Pubitemid 43291216)
100. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, Keegan AD, Garcia KC. 2008. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 132:259-272. (Pubitemid 351172435)
101. Lauffenburger DA, Linderman J, Berkowitz L. 1987. Analysis of mammalian cell growth factor receptor dynamics. Ann N Y Acad Sci 506:147-162. (Pubitemid 18585150)
102. Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor tyrosine kinases. Cell 141:1117-1134.
103. LeSauteur L, Maliartchouk S, Le Jeune H, Quirion R, Saragovi HU. 1996. Potent human p140-TrkA agonists derived from an anti-receptor monoclonal antibody. J Neurosci 16:1308-1316. (Pubitemid 26146986)
104. Levin D, Harari D, Schreiber G. 2011. Stochastic receptor expression determines cell fate upon interferon treatment. Mol Cell Biol 31:3252-3266.
105. Li L, Blumenthal DK, Terry CM, He Y, Carlson ML, Cheung AK. 2011. PDGF-induced proliferation in human arterial and venous smooth muscle cells: Molecular basis for differential effects of PDGF isoforms. J Cell Biochem 112:289-298.
106. Liu W, Brooks CL. 2011. Functional impact of manipulation on the relative orientation of human prolactin receptor domains. Biochemistry 50:5333-5344.
107. Livnah O, Johnson DL, Stura EA, Farrell FX, Barbone FP, You Y, Liu KD, Goldsmith MA, He W, Krause CD, Pestka S, Jolliffe LK, Wilson IA. 1998. An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol 5:993-1004. (Pubitemid 28506633)
108. Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA. 1996. Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 A. Science 273:464-471. (Pubitemid 26286442)
109. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. 1999. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283:987-990.
110. Lopez AF, Hercus TR, Ekert P, Littler DR, Guthridge M, Thomas D, Ramshaw HS, Stomski F, Perugini M, D'Andrea R, Grimbaldeston M, Parker MW. 2010. Molecular basis of cytokine receptor activation. IUBMB Life 62:509-518.
111. Lu X, Gross AW, Lodish HF. 2006. Active conformation of the erythropoietin receptor: Random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J Biol Chem 281:7002-7011. (Pubitemid 43847463)
112. Macdonald JL, Pike LJ. 2008. Heterogeneity in EGF-binding affinities arises from negative cooperativity in an aggregating system. Proc Natl Acad Sci USA 105:112-117.
113. Macdonald-Obermann JL, Pike LJ. 2009. The intracellular juxtamembrane domain of the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF binding. J Biol Chem 284:13570-13576.
114. Maeda Y, Kinoshita T. 2011. Structural remodeling, trafficking and functions of glycosylphosphatidylinositol-anchored proteins. Prog Lipid Res 50:411-424.
115. Malek TR, Castro I. 2010. Interleukin-2 receptor signaling: At the interface between tolerance and immunity. Immunity 33:153-165.
116. Massa SM, Yang T, Xie Y, Shi J, Bilgen M, Joyce JN, Nehama D, Rajadas J, Longo FM. 2010. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 120:1774-1785.
117. Massagué J. 2012. TGF-β signaling in development and disease. FEBS Lett 586:1833.
118. McClure BJ, Hercus TR, Cambareri BA, Woodcock JM, Bagley CJ, Howlett GJ, Lopez A F. 2003. Molecular assembly of the ternary granulocyte-macrophage colony-stimulating factor receptor complex. Blood 101:1308-1315. (Pubitemid 36182500)
119. Mendrola JM, Berger MB, King MC, Lemmon MA. 2002. The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem 277:4704-4712. (Pubitemid 34968501)
120. Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. 2012. IL-6/ IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci 122:143-159.
121. Mineev KS, Bocharov EV, Pustovalova YE, Bocharova OV, Chupin VV, Arseniev AS. 2010. Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases. J Mol Biol 400:231-243.
122. Mori E, Thomas M, Motoki K, Nakazawa K, Tahara T, Tomizuka K, Ishida I, Kataoka S. 2004. Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 11:203-207. (Pubitemid 38159644)
123. Motegi A, Fujimoto J, Kotani M, Sakuraba H, Yamamoto T. 2004. ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 117:3319-3329. (Pubitemid 39139916)
124. Nagy P, Claus J, Jovin TM, Arndt-Jovin DJ. 2010. Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis. Proc Natl Acad Sci USA 107:16524-16529.
125. Naismith JH, Brandhuber BJ, Devine TQ, Sprang SR. 1996a. Seeing double: Crystal structures of the type I TNF receptor. J Mol Recognit 9:113-117. (Pubitemid 26369486)
126. Naismith JH, Devine TQ, Kohno T, Sprang SR. 1996b. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure 4:1251-1262. (Pubitemid 26420495)
127. Nakamura M, Uehara Y, Asada M, Honda E, Nagai N, Kimata K, Suzuki M, Imamura T. 2011. Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho. J Biol Chem 286:26418-26423.
128. Nozaki C, Asai N, Murakami H, Iwashita T, Iwata Y, Horibe K, Klein RD, Rosenthal A, Takahashi M. 1998. Calcium-dependent Ret activation by GDNF and neurturin. Oncogene 16:293-299. (Pubitemid 28052283)
129. Oates J, King G, Dixon AM. 2010. Strong oligomerization behavior of PDGFβ receptor transmembrane domain and its regulation by the juxtamembrane regions. Biochim Biophys Acta 1798:605-615.
130. Oberholtzer E, Contarini M, Veglia F, Cossarizza A, Franceschi C, Geuna M, Provinciali M, Di Stefano G, Sissom J, Brizzi M F, Pegoraro L, Matera L. 1996. Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors. Adv Neuroimmunol 6:233-247. (Pubitemid 26412644)
131. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S. 2002. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775-787. (Pubitemid 35291060)
132. Ohashi H, Maruyama K, Liu YC, Yoshimura A. 1994. Ligand-induced activation of chimeric receptors between the erythropoietin receptor and receptor tyrosine kinases. Proc Natl Acad Sci USA 91:158-162. (Pubitemid 24018662)
133. Ozcan F, Klein P, Lemmon MA, Lax I, Schlessinger J. 2006. On the nature of low-and high-affinity EGF receptors on living cells. Proc Natl Acad Sci USA 103:5735-5740.
134. Pang X, Zhou HX. 2012. A common model for cytokine receptor activation: Combined scissor-like rotation and self-rotation of receptor dimer induced by class I cytokine. PLoS Comput Biol 8:e1002427.
135. Pawson T, Nash P. 2003. Assembly of cell regulatory systems through protein interaction domains. Science 300:445-452. (Pubitemid 36444318)
136. Pehar M, Cassina P, Vargas MR, Xie Y, Beckman JS, Massa SM, Longo FM, Barbeito L. 2006. Modulation of p75-dependent motor neuron death by a small non-peptidyl mimetic of the neurotrophin loop 1 domain. Eur J Neurosci 24:1575-1580. (Pubitemid 44427526)
137. Pellegrini L, Burke D F, von Delft F, Mulloy B, Blundell TL. 2000. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407:1029-1034.
138. Peng WC, Lin X, Torres J. 2009. The strong dimerization of the transmembrane domain of the fibroblast growth factor receptor (FGFR) is modulated by C-terminal juxtamembrane residues. Protein Sci 18:450-459.
139. Pestka S, Krause CD, Walter MR. 2004. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8-32. (Pubitemid 39576902)
140. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. 1996. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: One high-affinity and one low-affinity interaction. Biochemistry 35:1681-1691. (Pubitemid 26055303)
141. Piek E, Heldin CH, Ten Dijke P. 1999. Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 13:2105-2124.
142. Pietronave S, Forte G, Locarno D, Merlin S, Zamperone A, Nicotra G, Isidoro C, Nardo PD, Prat M. 2010. Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis. Am J Physiol Heart Circ Physiol 298:H1155-H1165.
143. Pless M, Norga K, Carroll M, Heim MH, D'Andrea AD, Mathey-Prevot B. 1997. Receptors that induce erythroid differentiation of Ba/F3 cells: structural requirements and effect on STAT5 binding. Blood 89:3175-3185.
144. Poger D, Mark AE. 2010. Turning the growth hormone receptor on: Evidence that hormone binding induces subunit rotation. Proteins 78:1163-1174.
145. Pollack SJ, Harper SJ. 2002. Trk Neurotrophin Receptor Activators. Drug
146. Posner BI, Laporte SA. 2010. Cellular signalling: Peptide hormones and growth factors. Prog Brain Res 181:1-16.
147. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. 1998. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 111 (Pt 2):237-247. (Pubitemid 28064148)
148. Qiu H, Belanger A, Yoon HW, Bunn HF. 1998. Homodimerization restores biological activity to an inactive erythropoietin mutant. J Biol Chem 273:11173-11176. (Pubitemid 28204966)
149. Qureshi SA, Kim RM, Konteatis Z, Biazzo DE, Motamedi H, Rodrigues R, Boice JA, Calaycay JR, Bednarek MA, Griffin P, Gao YD, Chapman K, Mark D F. 1999. Mimicry of erythropoietin by a nonpeptide molecule. Proc Natl Acad Sci USA 96:12156-12161. (Pubitemid 29502874)
150. Radaev S, Zou Z, Huang T, Lafer EM, Hinck AP, Sun PD. 2010. Ternary complex of transforming growth factor-β1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily. J Biol Chem 285:14806-14814.
151. Rao BM, Driver I, Lauffenburger DA, Wittrup KD. 2004. Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect. Mol Pharmacol 66:864-869. (Pubitemid 39319458)
152. Rawlings JS, Rosler KM, Harrison DA. 2004. The JAK/STAT signaling pathway. J Cell Sci 117:1281-1283. (Pubitemid 38559804)
153. Remy I, Wilson IA, Michnick SW. 1999. Erythropoietin receptor activation by a ligand-induced conformation change. Science 283:990-993.
154. Roessler E, Grant A, Ju G, Tsudo M, Sugamura K, Waldmann TA. 1994. Cooperative interactions between the interleukin 2 receptor alpha and beta chains alter the interleukin 2-binding affinity of the receptor subunits. Proc Natl Acad Sci USA 91:3344-3347. (Pubitemid 24130233)
155. Rowlinson SW, Behncken SN, Rowland JE, Clarkson RW, Strasburger CJ, Wu Z, Baumbach W, Waters MJ. 1998. Activation of chimeric and full-length growth hormone receptors by growth hormone receptor monoclonal antibodies. A specific conformational change may be required for full-length receptor signaling. J Biol Chem 273:5307-5314. (Pubitemid 28108697)
156. Rui H, Lebrun JJ, Kirken RA, Kelly PA, Farrar WL. 1994. JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology 135:1299-1306. (Pubitemid 24307502)
157. Saffarian S, Li Y, Elson EL, Pike LJ. 2007. Oligomerization of the EGF receptor investigated by live cell fluorescence intensity distribution analysis. Biophys J 93:1021-1031. (Pubitemid 47219793)
158. Saito Y, Honjo T. 1990. Why are multiple chains required for the interleukin 2 receptor? Prog Growth Factor Res 2:207-222. (Pubitemid 120038834)
159. Sathyanarayana P, Houde E, Marshall D, Volk A, Makropoulos D, Emerson C, Pradeep A, Bugelski PJ, Wojchowski DM. 2009. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood 113:4955-4962.
160. Schlee S, Carmillo P, Whitty A. 2006. Quantitative analysis of the activation mechanism of the multicomponent growth-factor receptor Ret. Nat Chem Biol 2:636-644. (Pubitemid 44610348)
161. Schlessinger J, Ullrich A. 1992. Growth factor signaling by receptor tyrosine kinases. Neuron 9:383-391.
162. Schneider H, Chaovapong W, Matthews DJ, Karkaria C, Cass RT, Zhan H, Boyle M, Lorenzini T, Elliott SG, Giebel LB. 1997. Homodimerization of erythropoietin receptor by a bivalent monoclonal antibody triggers cell proliferation and differentiation of erythroid precursors. Blood 89:473-482. (Pubitemid 27051682)
163. Schneider MR, Wolf E. 2009. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 218:460-466.
164. Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, Krishnakumar S, Smith SO, Constantinescu SN. 2003. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 12:1239-1250. (Pubitemid 37487931)
165. Shalaby MR, Sundan A, Loetscher H, Brockhaus M, Lesslauer W, Espevik T. 1990. Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J Exp Med 172:1517-1520. (Pubitemid 20366229)
166. Sharpe S, Barber KR, Grant CW. 2002a. Evidence of a tendency to self-association of the transmembrane domain of ErbB-2 in fluid phospholipid bilayers. Biochemistry 41:2341-2352. (Pubitemid 34160896)
167. Sharpe S, Barber KR, Grant CW. 2002b. Interaction between ErbB-1 and ErbB-2 transmembrane domains in bilayer membranes. FEBS Lett 519:103-107. (Pubitemid 34522000)
168. Shikama Y, Barber DL, D'Andrea AD, Sieff CA. 1996. A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines. Blood 88:455-464. (Pubitemid 26240376)
169. Sieber C, Kopf J, Hiepen C, Knaus P. 2009. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 20:343-355.
170. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D, Tsien RY, Lenardo MJ. 2000. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288:2354-2357. (Pubitemid 30448157)
171. Simons K, Sampaio JL. 2011. Membrane organization and lipid rafts. Cold Spring Harb Perspect Biol 3:a004697.
172. Singh AB, Harris RC. 2005. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 17:1183-1193. (Pubitemid 40984037)
173. Skaper SD. 2008. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets 7:46-62. (Pubitemid 351516216)
174. Skaper SD. 2011. Peptide mimetics of neurotrophins and their receptors. Curr Pharm Des 17:2704-2718.
175. Sogo T, Kawahara M, Ueda H, Otsu M, Onodera M, Nakauchi H, Nagamune T. 2009. T cell growth control using hapten-specific antibody/interleukin-2 receptor chimera. Cytokine 46:127-136.
176. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. 2006. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood 107:1864-1871. (Pubitemid 43289364)
177. Stahl N, Yancopoulos GD. 1993. The αs, βs, and kinases of cytokine receptor complexes. Cell 74:587-590.
178. Stark GR, Darnell JE Jr. 2012. The JAK-STAT pathway at twenty. Immunity 36:503-514.
179. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. 2006. Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci USA 103:2788-2793.
180. Stroud RM, Wells JA. 2004. Mechanistic diversity of cytokine receptor signaling across cell membranes. Sci STKE 2004:re7.
181. Strunk JJ, Gregor I, Becker Y, Li Z, Gavutis M, Jaks E, Lamken P, Walz T, Enderlein J, Piehler J. 2008. Ligand binding induces a conformational change in ifnar1 that is propagated to its membrane-proximal domain. J Mol Biol 377:725-739.
182. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, Stroud RM. 1998. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395:511-516. (Pubitemid 28462447)
183. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T. 1993. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90:11924-11928. (Pubitemid 24008752)
184. Tao RH, Maruyama IN. 2008. All EGF(ErbB) receptors have preformed homo-and heterodimeric structures in living cells. J Cell Sci 121:3207-3217.
185. Tarasova A, Haylock D, Winkler D. 2011. Principal signalling complexes in haematopoiesis: Structural aspects and mimetic discovery. Cytokine Growth Factor Rev 22:231-253.
186. Tenhumberg S, Schuster B, Zhu L, Kovaleva M, Scheller J, Kallen KJ, Rose-John S. 2006. gp130 dimerization in the absence of ligand: Preformed cytokine receptor complexes. Biochem Biophys Res Commun 346:649-657.
187. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, Lee C, Yarden G, Vleck SE, Glenn JS, Nolan GP, Piehler J, Schreiber G, Garcia KC. 2011. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 146:621-632.
188. Tian SS, Lamb P, King AG, Miller SG, Kessler L, Luengo JI, Averill L, Johnson RK, Gleason JG, Pelus LM, Dillon SB, Rosen J. 1998. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor [see commetns]. Science 281:257-259. (Pubitemid 28334508)
189. Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, Gray C, Armanini MP, Pollock RA, Hefti F, Phillips HS, Goddard A, Moore MW, Buj-Bello A, Davies AM, Asai N, Takahashi M, Vandlen R, Henderson CE, Rosenthal A. 1996. Characterization of a multicomponent receptor for GDNF. Nature 382:80-83. (Pubitemid 26243362)
190. Tsunekawa B, Wada M, Ikeda M, Uchida H, Naito N, Honjo M. 1999. The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the effect on the human prolactin receptor. Endocrinology 140:3909-3918. (Pubitemid 30647084)
191. Ullrich A, Schlessinger J. 1990. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212.
192. Vadas O, Hartley O, Rose K. 2008. Characterization of new multimeric erythropoietin receptor agonists. Biopolymers 90:496-502.
193. van Agthoven J, Zhang C, Tallet E, Raynal B, Hoos S, Baron B, England P, Goffin V, Broutin I. 2010. Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone. J Mol Biol 404:112-126.
194. Viswanathan S, Benatar T, Rose-John S, Lauffenburger DA, Zandstra PW. 2002. Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6. Stem Cells 20:119-138. (Pubitemid 34297260)
195. Wang X, Lupardus P, Laporte SL, Garcia KC. 2009. Structural biology of shared cytokine receptors. Annu Rev Immunol 27:29-60.
196. Ward LD, Howlett GJ, Discolo G, Yasukawa K, Hammacher A, Moritz RL, Simpson RJ. 1994. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem 269:23286-23289. (Pubitemid 24283319)
197. Watowich SS, Hilton DJ, Lodish HF. 1994. Activation and inhibition of erythropoietin receptor function: Role of receptor dimerization. Mol Cell Biol 14:3535-3549. (Pubitemid 24160761)
198. Watowich SS, Yoshimura A, Longmore GD, Hilton DJ, Yoshimura Y, Lodish HF. 1992. Homodimerization and constitutive activation of the erythropoietin receptor. Proc Natl Acad Sci USA 89:2140-2144.
199. Watowich SS. 1999. Activation of erythropoietin signaling by receptor dimerization. Int J Biochem Cell Biol 31:1075-1088. (Pubitemid 29454547)
200. Weidemann T, Höfinger S, Müller K, Auer M. 2007. Beyond dimerization: A membrane-dependent activation model for interleukin-4 receptor-mediated signalling. J Mol Biol 366:1365-1373. (Pubitemid 46215599)
201. Whitson KB, Beechem JM, Beth AH, Staros J V. 2004. Preparation and characterization of Alexa Fluor 594-labeled epidermal growth factor for fluorescence resonance energy transfer studies: Application to the epidermal growth factor receptor. Anal Biochem 324:227-236. (Pubitemid 38019013)
202. Whitty A, Borysenko CW. 1999. Small molecule cytokine mimetics. Chem Biol 6:R107-R118. (Pubitemid 29368406)
203. Whitty A, Raskin N, Olson DL, Borysenko CW, Ambrose CM, Benjamin CD, Burkly LC. 1998. Interaction affinity between cytokine receptor components on the cell surface. Proc Natl Acad Sci USA 95:13165-13170. (Pubitemid 28509542)
204. Whitty A, Riera TV. 2008. New ways to target old receptors. Curr Opin Chem Biol 12:427-433.
205. Whitty A. 2008. Cooperativity and biological complexity. Nat Chem Biol 4:435-439. (Pubitemid 352019765)
206. Wilson IA, Jolliffe LK. 1999. The structure, organization, activation and plasticity of the erythropoietin receptor. Curr Opin Struct Biol 9:696-704.
207. Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ. 1996. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273:458-464.
208. Wu Y, Vendome J, Shapiro L, Ben-Shaul A, Honig B. 2011. Transforming binding affinities from three dimensions to two with application to cadherin clustering. Nature 475:510-513.
209. Wu Z, Johnson KW, Goldstein B, Choi Y, Eaton SF, Laue TM, Ciardelli TL. 1995. Solution assembly of a soluble, heteromeric, high affinity interleukin-2 receptor complex. J Biol Chem 270:16039-16044.
210. Yarden Y, Schlessinger J. 1987. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 26:1443-1451. (Pubitemid 17045875)
211. Zabeau L, Defeau D, Van der Heyden J, Iserentant H, Vandekerckhove J, Tavernier J. 2004. Functional analysis of leptin receptor activation using a Janus kinase/signal transducer and activator of transcription complementation assay. Mol Endocrinol 18:150-161. (Pubitemid 38073161)
212. Zaccaro MC, Lee HB, Pattarawarapan M, Xia Z, Caron A, L'Heureux PJ, Bengio Y, Burgess K, Saragovi HU. 2005. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chem Biol 12:1015-1028. (Pubitemid 41338812)
213. Zaks-Zilberman M, Harrington AE, Ishino T, Chaiken IM. 2008. Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging. J Biol Chem 283:13398-13406.
214. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149. (Pubitemid 43866200)
215. Zhou ZH, Wang JF, Wang YD, Qiu YH, Pan JZ, Xie W, Jiang LY, Klein B, Zhang XG. 1999. An agonist anti-human CD40 monoclonal antibody that induces dendritic cell formation and maturation and inhibits proliferation of a myeloma cell line. Hybridoma 18:471-478. (Pubitemid 30020608)
216. Zhu DM, Dustin ML, Cairo CW, Golan DE. 2007. Analysis of two-dimensional dissociation constant of laterally mobile cell adhesion molecules. Biophys J 92:1022-1034. (Pubitemid 46203232)
217. Zhu HJ, Sizeland AM. 1999. A pivotal role for the transmembrane domain in transforming growth factor-β receptor activation. J Biol Chem 274:11773-11781.
218. Zúñiga JE, Groppe JC, Cui Y, Hinck CS, Contreras-Shannon V, Pakhomova ON, Yang J, Tang Y, Mendoza V, López-Casillas F, Sun L, Hinck A P. 2005. Assembly of TbetaRI: TbetaRII: TGFbeta ternary complex in vitro with receptor extracellular domains is cooperative and isoform-dependent. J Mol Biol 354:1052-1068. (Pubitemid 41698915)